There is actually 70 m savings in operating expenses , so Mayne is operating both Nexstellis and TXMD at profit for the first time , so they are correct 14 m +ve contribution and international segment always making profit , hopefully they add more dermatology products from similar companies to use the existing sales force . Smart idea
- Forums
- ASX - By Stock
- MYX
- Mayne Pharma sees strong sales growth in FY 2023
Mayne Pharma sees strong sales growth in FY 2023, page-70
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
|
|||||
Last
$4.26 |
Change
-0.110(2.52%) |
Mkt cap ! $362.4M |
Open | High | Low | Value | Volume |
$4.36 | $4.36 | $4.25 | $253.7K | 59.12K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 1090 | $4.25 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.26 | 2303 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 1090 | 4.250 |
1 | 141 | 4.240 |
2 | 645 | 4.230 |
3 | 6645 | 4.220 |
2 | 645 | 4.210 |
Price($) | Vol. | No. |
---|---|---|
4.260 | 2303 | 4 |
4.280 | 1645 | 3 |
4.290 | 645 | 2 |
4.300 | 645 | 2 |
4.310 | 141 | 1 |
Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online